A61P 25/10
For petit-mal
Official title: for petit-mal
A61P25/10 (For petit-mal) appears on 247 US grants and 383 published applications in this corpus.
Search patents in A61P- Granted patents
- 247
- Published applications
- 383
- Assignees
- 156
- Inventors
- 797
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 3 | 0 |
| 2002 | 5 | 9 |
| 2003 | 4 | 11 |
| 2004 | 5 | 15 |
| 2005 | 5 | 22 |
| 2006 | 10 | 31 |
| 2007 | 15 | 34 |
| 2008 | 12 | 33 |
| 2009 | 13 | 29 |
| 2010 | 15 | 29 |
| 2011 | 23 | 18 |
| 2012 | 16 | 19 |
| 2013 | 13 | 19 |
| 2014 | 20 | 15 |
| 2015 | 18 | 17 |
| 2016 | 14 | 16 |
| 2017 | 6 | 17 |
| 2018 | 12 | 3 |
| 2019 | 6 | 9 |
| 2020 | 7 | 8 |
| 2021 | 6 | 7 |
| 2022 | 4 | 8 |
| 2023 | 3 | 4 |
| 2024 | 4 | 3 |
| 2025 | 2 | 4 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Oxadiazole derivative12 May 2026US 12,624,011 B2Sumitomo Pharma Co., Ltd.
- Piperazine azaspiro derivatives26 Aug 2025US 12,398,119 B2Pfizer Inc.
- Use of cannabinoids in the treatment of epilepsy12 Aug 2025US 12,383,567 B2Jazz Pharmaceuticals Research UK Limited
- Oligosaccharides for use in the treatment of Parkinson's disease12 Nov 2024US 12,138,277 B2Universita' Degli Studi Di Milano
- Use of cannabinoids in the treatment of epilepsy20 Aug 2024US 12,064,399 B2Jazz Pharmaceuticals Research UK Limited
- Oxadiazole derivative20 Aug 2026US 2026/0242345 A1Sumitomo Pharma Co., Ltd.
- Cannabidiol for the treatment of refractory seizures23 Jul 2026US 2026/0207635 A1Harmony Biosciences Management, Inc.
- Methods of treatment19 Feb 2026US 2026/0048069 A1Arena Pharmaceuticals, Inc.
- Cannabinoids in the treatment of epilepsy13 Nov 2025US 2025/0345349 A1Jazz Pharmaceutical Research UK Limited
- Pharmaceutical combination for preventing or treating epileptic seizure and the use thereof10 Jul 2025US 2025/0222057 A1Fu Jen Catholic University
Most cited
By later US patents
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006
- Albumin fusion proteins96US 7,592,010 B2Delta Biotechnology Limited · 2009
- Use of cannabinoids in the treatment of epilepsy78US 9,474,726 B2GW Pharma Limited · 2016
- Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy74US 9,066,920 B2GW Pharma Limited · 2015
- Use of cannabinoids in the treatment of epilepsy73US 9,956,185 B2GW Pharma Limited · 2018